Redsense participates in US congress briefing on VND
Redsense Medical successfully participated in a virtual briefing about venous needle dislodgement (VND) for US congress on March 14, 2022. The briefing raised awareness and educated the Congressional participants about the risks and serious consequences of venous needle dislodgement occuring in connection with dialysis treatments. Presenting on behalf of Redsense was the company’s US Clinical Director Jane Hurst. The briefing was held as a virtual event, and involved the participation of multiple professional renal organizations and advocacy associations in addition to Redsense, among